Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences

11/01/2021 | 05:30am EST

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it will participate in four upcoming virtual investor conferences during the months of November and December.

Event:Virtual Guggenheim 3rd Annual Neuro/Immunology Conference
Date:November 15, 2021
Format:One-on-one meetings with members of the investor relations team
  
Event:Stifel 2021 Virtual Healthcare Conference
Date:November 16, 2021
Format:Fireside chat with Chairperson and CEO Tony Coles, M.D.
 One-on-one meetings with members of the management team
Time:8:40 a.m. ET
  
Event:Jefferies London Healthcare Conference
Date:November 18, 2021
Format:One-on-one meetings with members of the management team
  
Event:Evercore ISI HealthCONx Conference
Date:December 1, 2021
Format:Fireside chat with Chairperson and CEO Tony Coles, M.D.
 One-on-one meetings with members of the management team
Time:9:40 a.m. ET

Live audio webcasts of the virtual conference fireside chats can be accessed on the investor relations section of the Cerevel Therapeutics website here. Replays will also be available in the same section of the company’s website.

About Cerevel Therapeutics
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson’s, epilepsy, schizophrenia, and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit www.cerevel.com.

Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our upcoming virtual investor conference participation and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading “Risk Factors” in our Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:
Kate Contreras
Real Chemistry
kcontreras@realchemistry.com

Investor Contact:
Matthew Calistri
Cerevel Therapeutics
matthew.calistri@cerevel.com


Primary Logo

Source: Cerevel Therapeutics

2021 GlobeNewswire, Inc., source Press Releases

All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
01/10CEREVEL THERAPEUTICS TO PRESENT AT 4 : Additional Details of Phase 2 Program for Emraclidi..
AQ
01/05JPMorgan Starts Cerevel Therapeutics Holdings at Overweight With $50 Price Target
MT
01/03Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2021INSIDER SELL : Cerevel Therapeutics Holdings
MT
2021Cerevel Agrees Multi-year Collaboration With Herophilus to Research, Develop Therapeuti..
MT
2021HC Wainwright Starts Cerevel Therapeutics Holdings at Buy With $50 Price Target
MT
2021CVL-231 : Results From an Early Proof-Of-Concept Study in Patients With Schizophrenia
PU
2021CEREVEL THERAPEUTICS : Evaluation of M4 Muscarinic Receptor Occupancy by CVL-231 in Nonhum..
PU
2021Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates ..
PU
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -221 M - -
Net cash 2021 609 M - -
P/E ratio 2021 -14,7x
Yield 2021 -
Capitalization 3 500 M 3 500 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 168
Free-Float -
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 23,77 $
Average target price 47,80 $
Spread / Average Target 101%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.-27.36%3 467
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-11.62%47 040
BIONTECH SE-40.05%37 325